会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • ARMET AS A MARKER FOR CANCER
    • ARMET ALS KREBSMARKER
    • EP2380024A1
    • 2011-10-26
    • EP09798890.1
    • 2009-12-18
    • Roche Diagnostics GmbHF. Hoffmann-La Roche AG
    • ROESSLER, MarkusKARL, JohannRIEDLINGER, JuliaLINDNER, IngoTACKE, Michael
    • G01N33/574
    • G01N33/57488G01N33/57423G01N33/57484G01N2333/475G01N2800/52
    • The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the arginine-rich metastasized in early tumors protein (= ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g. of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are e.g. breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in said sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    • 披露了一种帮助评估癌症的方法。 更具体地公开了在早期肿瘤蛋白(= ARMET)中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌(LC)或结肠癌,例如非小细胞肺癌(NSCLC)或结肠直肠癌(CRC),但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺,卵巢,子宫颈,头颈部,子宫内膜,黑素瘤,膀胱,肾,胰腺,前列腺,食道,胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 ARMET的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。